Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 759 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cystic Lung Disease Clear all
Enrolling by invitation No phase listed Observational

Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening

NCT04579211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
urine lipoarabinomannan (LAM)
Diagnostic Test
Lead sponsor
Jerry A. Nick, M.D.
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Acceptability, Feasibility and Preliminary Efficacy of CFWP to Treat Clinically Elevated Fatigue in Adults With CF

NCT04809207
View directory record Official record
Conditions
Cystic Fibrosis, Fatigue
Interventions
CF Wellness Program Sessions
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 23, 2026, 3:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects

NCT01078740
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Birmingham, Alabama • Iowa City, Iowa • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Results available

PTC Study to Evaluate Ataluren in Combination With Ivacaftor

NCT03256968
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

NCT01707290
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 23, 2026, 3:47 PM EDT
Completed No phase listed Observational

Genetics of Mammographic Appearances and Patterns (The GenMap Study)

NCT01160510
View directory record Official record
Conditions
Benign Breast Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

NCT01768663
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 23, 2026, 3:47 PM EDT
Completed No phase listed Observational

The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

NCT01616862
View directory record Official record
Conditions
Pseudomonas Aeruginosa, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Zafer Soultan
Other
Eligibility
5 Years to 19 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 23, 2026, 3:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

NCT00846573
View directory record Official record
Conditions
COPD, Cystic Fibrosis, Asthma, Healthy
Interventions
Hyperpolarized Helium-3
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Sep 23, 2026, 3:47 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

High Resolution Micro OCT Imaging

NCT03256773
View directory record Official record
Conditions
Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

28 Day Repeat Dose in Cystic Fibrosis Patients

NCT00903201
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SB656933, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 23, 2026, 3:47 PM EDT
Not yet recruiting Phase 2 Interventional

Verapamil Effect in Cystic Fibrosis-related Dysglycemia

NCT07688070
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
Interventions
Verapamil Hydrochloride
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 23, 2026, 3:47 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical Students

NCT03041571
View directory record Official record
Conditions
Narrative Medicine, Chronic Disease, Terminal Illness, Cancer, Diabetes Mellitus, Cystic Fibrosis, Rheumatologic Disorder, Oncologic Disorders, Hematologic Diseases
Interventions
Patient Provider Orientation Scale, Interview performed by MHP student
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 2Phase 3 Interventional

Saline Hypertonic in Preschoolers + CT

NCT02950883
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Active Treatment Group 7% Hypertonic Saline, Control Group 0.9% Isotonic Saline
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
7
States / cities
Aurora, Colorado • Indianapolis, Indiana • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

NCT01931839
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
91
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 23, 2026, 3:47 PM EDT
Recruiting No phase listed Observational

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

NCT07312734
View directory record Official record
Conditions
Cystic Fibrosis (CF), New Diagnostics
Interventions
Not listed
Lead sponsor
Chris Goss
Other
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
La Jolla, California • Minneapolis, Minnesota • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 23, 2026, 3:47 PM EDT
Completed No phase listed Observational

Study of Peripherally Inserted Venous Catheters in Cystic Fibrosis Patients

NCT03674216
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Jonathan B. Zuckerman
Other
Eligibility
6 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis

NCT00530244
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Docosahexaenoic acid (DHA), Standard formula (Enfamil)
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Up to 56 Days
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Atlanta, Georgia • Des Moines, Iowa + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 23, 2026, 3:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations

NCT00381628
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
epithelial cells and blood lymphocyte extraction
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis

NCT00546663
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled 7% hypertonic saline (HS)
Drug
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
12 Months to 30 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Sep 23, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

NCT03447249
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
48
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 23, 2026, 3:47 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 3:47 PM EDT